Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 1
TMF Doc ID: 98.03Protocol B5091009
A PH ASE 2, PL ACEBO -CONTROLLED, RANDOMIZED, OBSERVER -BLINDED 
STUDY TO EVALUATE THE SAF ETY, TOLERABILITY, AND IMMUNOGEN ICITY 
OF TWO 3- DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN 
HEALTHY ADULTS AGED 65 TO 85 YEARS
Statistica l Analy sis Plan 
(SAP)
Version : 2.0
Date: 17-June- 201 6

Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 2
TMF Doc ID: 98.03TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....4
1. VERSION HISTORY............................................................................................................52. INTRODUCTION ................................................................................................................ .5
2.1. Study Objectives .......................................................................................................5
2.1.1. Primary Immunogenicity  Objectives (PI).....................................................5
2.1.2. Primary Safety Objective (PS)......................................................................52.1.3. Secondary Immunogenicity Objectives (SI).................................................62.1.4. Secondary Safety Objective (SS)..................................................................62.1.5.  ( ) ...........................................................................6
2.2. Study Design .............................................................................................................6
3. ENDPOINTS AND BASELINE VARIABLES: DEFINITIONS AND 
CONVENTIONS ..................................................................................................................7
3.1. Primary Endpoints.....................................................................................................7
3.1.1. Primary Immunogen icity Endpoints.............................................................7
3.1.2. Primary Safety Endpoints.............................................................................8
3.2. Secondary Endpoints.................................................................................................8
3.2.1. Secondary Immunoge nicity Endpoints.........................................................8
3.2.2. Secondary Safety Endpoints.......................................................................11
3.3. .................................................................113.4. ...................................................................................................113.5. Safety Endpoints .....................................................................................................12
3.5.1. Adverse Events ...........................................................................................123.5.2. ......................................................................123.5.3. Reactogenicity Endpoints ...........................................................................12
[IP_ADDRESS]. Local Reactions .........................................................................[IP_ADDRESS]. Systemic Events ........................................................................16
3.5.4. Antipyretics/Pain Medication Use..............................................................183.5.5. Vital Signs and Physical Examination........................................................[ADDRESS_398960] .........................................................................................................19
3.6.1. E-Diary Completion....................................................................................19CCI
CCICCICCI
CCI
Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 3
TMF Doc ID: [IP_ADDRESS]. Demographic, Medical History, and Baseline Characteristic 
Variables ..........................................................................................................20
3.6.3. Concomitant Treatment ..............................................................................21
4. ANALYSIS SETS ............................................................................................................... 21
4.1. Evaluable Analysis Set............................................................................................214.2. Modified Intent-to-Treat Analysis Set ....................................................................224.3. Safety Analysis Set..................................................................................................234.4. Other Analysis Sets .................................................................................................23
5. GENERAL METHODOLOGY AND CONVENTIONS....................................................23
5.1. Hypotheses and Decision Rules ..............................................................................245.2. General Methods .....................................................................................................24
5.2.1. Analyses for Bi nary Data............................................................................24
5.2.2. Analyses for Continuous Data....................................................................25
5.3. Methods to Manage Missing Data ..........................................................................26
5.3.1. Immunogenicity Data .................................................................................265.3.2. Safety  Data..................................................................................................26
6. ANALYSES AND SUMMARIES ......................................................................................27
6.1. Primary Endpoint(s) ................................................................................................27
6.1.1. Primary Immunogen icity Endpoints...........................................................27
[IP_ADDRESS]. Primary Analysis .......................................................................[ADDRESS_398961] ............................................................................................33
[IP_ADDRESS]. Subject Disposition, Vaccination Administration, Blood 
Samples, and Screen Failures ............................................................33
[IP_ADDRESS]. Demographic, Medical History, and Baseline 
Characteristics ...................................................................................33CCI
Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 4
TMF Doc ID: [IP_ADDRESS].3. E-Diary Completion ..................................................................34
6.4.3. Analyses of Below LLOQ ..........................................................................34
6.5. Safety Summaries and Analyses .............................................................................34
6.5.1. Adverse Events ...........................................................................................346.5.2. Reactogenicity Data....................................................................................35
[IP_ADDRESS]. Unscheduled Visits (Unplanned Visits) for Severe 
Reactions ...........................................................................................[ADDRESS_398962] OF TABLES
Table 1. Summary of Major Changes in SAP Amendments ................................................5
Table 2. Vaccine Groups and Number of Subjects per Group and per Dose Regimen........7Table 3. Derived Variables for Each Local Reaction Within a Specified Time 
Interval..................................................................................................................14
Table 4. Derived Variables for Any Local Reaction Within a Specified Time 
Interval..................................................................................................................14
Table 5. Local Reaction Grading Scale ..............................................................................15Table 6. Systemic Event Grading Scale..............................................................................17Table 7.  
..............................................................................................................31
CCI
CCICCI
Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 5
TMF Doc ID: 98.031.VERSION HISTORY
The statistical a nalysis plan (SAP) Version 1 for Study B5091009 wasbased on the protocol 
dated 01 April 2015 .This SAP amendment is based on 
protocol amendment 1 dated 
11April 2016.
Table 1. Summary of Major Changes in SAP Amendments
SAP 
Versio
nChange Rationale
1.0 Not applicable Not applicable
2.0 Major changes include adding objectives, endpoints ,
and analysis for the extension stage of the study and an 
additional interim analysis discussed in protocol 
amendment 1Protocol amendment 1, 11 A pril 2016
2.INTRODUCTION
This SAP provides the detailed methodology  for summary and statistical analy ses of the data 
collected in Study B5091009 .  This document may modify the plans outlined in the protocol; 
however, an y major modifications of the primary endpoint definition or its anal ysis will also 
be reflected in a protocol amendment.
2.1. Study Objectives
2.1.1. Primary Immunogenicity Objectives (PI)
To describe the immunogenicity  of 2 antigen dose levels (100 µg and 200 µg total 
toxoid) of C lostridium difficile vaccine when administered as a 3 -dose regimen (Day s 1, 
8, and 30) to healthy adults aged 65 to 85 years, as measured b y Cdifficile toxin A –and 
toxin B –specific neutralizing antibody  levels at Day  37 (7 day s after Dose 3).
To describe the immunogenicity  of 2 antigen dose levels (100 µg and 200 µg total 
toxoid) of 
Cdifficile vaccine when administered as a 3 -dose regimen (Months 0, 1 ,and 6) 
to healthy  adults aged 65 to 85 y ears, as measured by  [CONTACT_233011] A – and toxin B–
specific neutralizing antibody  levels at Month 7 (1 month after Dose 3).
2.1.2. Primary Safety Objective (PS)
To assess the safet y and tolerability of 2 antigen dose levels (100 µg and 200 µg total 
toxoid) of C difficile vaccine when administered as a 3 -dose regimen (either Day s 1, 8, 
and 30 or Months 0, 1, and 6) to healthy  adults aged 65 to 85 y ears, by  [CONTACT_323287] s ystemic events reported on subjects’ electronic diaries (e -diaries), adverse 
events (AEs), and serious AEs (SAEs).

Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 6
TMF Doc ID: [IP_ADDRESS]. Secondary Immunogenicity Objectives (SI)
To describe the immunogenicity of 2 antigen dose levels (100 μg and 200 μg total 
toxoid) of C difficile vaccine when administered in a 3-dose regimen (either Days 1, 8, 
and 30 or Months 0, 1, and 6) to healthy adults aged 65 to 85 years, as measured by C difficile toxin A– and toxin B–specific neutralizing antibody levels at multiple time 
points following vaccination.
To describe the kinetics of the immune response in healthy adults aged 65 to 85 years for 
up to 12 months following the administration of 3 doses of C difficile vaccine.
To describe the immunogenicity of a fourth dose of C difficile vaccine as measured by 
C difficile toxin A– and toxin B–specific neutralizing antibody levels at multiple time 
points following vaccination.
To describe the kinetics of the immune response in healthy adults aged 65 to 85 years for 
up to 36 months following the administration of a fourth dose of C difficile vaccine.
2.1.4. Secondary Safety Objective (SS)
To assess the safety and tolerability of a fourth dose of C difficile vaccine by [CONTACT_323288]’ e-diaries, AEs, and SAEs.
2.1.5.  ( )
  
 
  
  
2.2. Study Design
This is a Phase 2, placebo-controlled, randomized, observer-blinded study to assess the 
safety, tolerability, and immunogenicity of 2 antigen dose levels (100 μg and 200 μg total 
toxoid) of aluminum hydroxide–containing C difficile vaccine administered as a 3-dose 
regimen: either at Days 1, 8, and 30 or at Months 0, 1, and 6.
Subjects will be assigned to 1 of the 2 dosing regimens (Days 1, 8, and 30 or Months 0, 1, 
and 6) and then randomly assigned in parallel in a 3:3:1 ratio to receive C difficile vaccine 
(100 μg or 200 μg total toxoid) or placebo (saline).CCI C
C
CCI
Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 7
TMF Doc ID: 98.03Subjects in both dosing regimens who received the first 3 doses of C difficile vaccine (100 µg 
or 200 µg) will be enrolled into an extension stage. These subjec ts will receive a fourth dose 
of either C difficile vaccine at the same antigen dose level (100 µg or 200 µg) as they  
received previousl y or placebo, approximatel y [ADDRESS_398963] dose. These subjects 
will be followed for a further 3 y ears (visits approximately  every  6 months) to assess 
antibody  persistence. Subjects originally  randomized to placebo in either dosing regimen will 
not continue into the extension stage.
Approximately  854 healthy  adults aged 65 to 85 years will be enrolled at approxima tely 15 
sites in the [LOCATION_002]. Subjects withdrawn from the study  after randomization will not be 
replaced, regardless of the reason for withdrawal.
For each dosing regimen, approximatel y 366 subjects will receive the C difficile vaccine 
(ateither 100 or 200 µg total toxoid dose level) and approximatel y 61 subjects will receive 
placebo (saline).
Table 2. Vaccine Groups and Number of Subjects per Group and per Dose Regimen
Vaccine 
GroupVaccine Formulation Description Dosing Reg imen Number of Subjects
1aAlum inum hydroxide –containing C difficile 
vaccine (100 -µg antigen dose)Days 1,8,30 183
2aAluminum hydroxide– containing C difficile 
vaccine (200 -µg antigen dose)Days 1,8,30 183
3 Placebo (saline) Days 1,8,30 61
4aAluminu m hydroxide –containing C difficile 
vaccine (100 -µg antigen dose)Months 0,1,6 183
5aAluminum hydroxide– containing C difficile 
vaccine (200 -µg antigen dose)Months 0,1,6 183
6 Placebo (saline) Months 0,1,6 61
Total 854
a.Subjects in these groups wil l be asked to enter the extension stage
All eligible subjects who received 3 doses of C difficile vaccine (Groups 1, 2, 4, and 5) will 
be asked to enter the extension stage. Subjects enrolled in the extension stage will be 
rerandomized to receive a fourt h dose of either C difficile vaccine at the same antigen dose 
level (100 µg or 200 µg) as they  received previously  or placebo.
3.ENDPOINTS AND BASELI NE VARIABLES: DEFINI TIONS AND 
CONVENTIONS
3.1.Primary Endpoints
3.1.1. Primary Immunogenicity Endpoints
At Day  37 (7 day s after Dose 3 for subjects receiving the Day  1, 8, and 30 regimen) and at 
Month 7 (1 month after Dose 3 for subjects receiving the Month 0, 1 ,and 6 regimen), the 
proportions of subjects in each vaccine group with:

Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 8
TMF Doc ID: 98.03Toxin A–specific neutralizing antibody level (neutralization units/mL) the specified 
threshold for toxin A;
Toxin B–specific neutralizing antibody level (neutralization units/mL) the specified 
threshold for toxin B; and 
Both toxin A– and toxin B–specific neutralizing antibody levels (neutralization units/mL) 
the specified threshold for toxin A and the specified threshold for toxin B, respectively.
3.1.2. Primary Safety Endpoints
Numbers and proportions of subjects reporting local reactions (pain, erythema, and 
induration) and their severity, as self-reported on e-diaries for up to 14 days following 
Vaccinations 1, 2, and 3.
Numbers and proportions of subjects reporting systemic events (fever, vomiting, 
diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint 
pain) and their severity, as self-reported on e-diaries for up to 14 days following  Vaccinations 1, 2, and 3.
Numbers and proportions of subjects reporting AEs from the first vaccination up to 
[ADDRESS_398964] vaccination, categorized according to the Medical Dictionary for 
Regulatory Activities (MedDRA).
Numbers and proportions of subjects reporting SAEs from the first vaccination until 
[ADDRESS_398965] vaccination, categorized according to MedDRA.
3.2. Secondary Endpoints
3.2.1. Secondary Immunogenicity Endpoints
At Day 37 (7 days after Dose 3 for subjects receiving the Day 1, 8, and 30 regimen) and at 
Month 7 (1 month after Dose 3 for subjects receiving the Month 0, 1, and 6 regimen):
Toxin A– and toxin B–specific neutralizing antibody levels, expressed as geometric mean 
concentrations (GMCs) (neutralization units/mL).
Geometric mean fold rises (GMFRs) from baseline (before Dose 1) in:
Toxin A–specific; and
Toxin B–specific neutralizing antibody levels (neutralization units/mL).CCI
Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 9
TMF Doc ID: 98.03Proportions of subjects in each vaccine group with 4-fold, 8-fold, 16-fold, and 
32-fold rises from baseline in:
Toxin A–specific;
Toxin B–specific; and
Both toxin A– and toxin B–specific neutralizing antibody levels (neutralization 
units/mL).
For subjects receiving the Day 1, 8, and 30 regimen, on Day 1 (immediately before Dose 1), 
Day 8 (immediately before Dose 2), Day 15 (7 days after Dose 2), Day 30 (immediately 
before Dose 3), and Months 2 (1 month after Dose 3), 4 (3 months after Dose 3), 7 (6 months 
after Dose 3), and 13 (12 months after Dose 3); or for subjects receiving the Month 0, 1, and 6 regimen, on Day 1 (immediately before Dose 1), Day 30 (immediately before Dose 2), Day 37 (7 days after Dose 2), Months 2 (1 month after Dose 2) and 6 (immediately before Dose 3), Day 187 (7 days after Dose 3), and Months 12 (6 months after Dose 3) and 18 (12 months after Dose 3):
Proportions of subjects in each vaccine group with:
Toxin A–specific neutralizing antibody level (neutralization units/mL) the specified 
threshold for toxin A;
Toxin B–specific neutralizing antibody level (neutralization units/mL) the specified 
threshold for toxin B; and 
Both toxin A– and toxin B–specific neutralizing antibody levels (neutralization 
units/mL) ≥ the specified threshold for toxin A and the specified threshold for toxin 
B, respectively (these parameters will also be assessed at baseline).
Toxin A– and toxin B–specific neutralizing antibody levels, expressed as GMCs 
(neutralization units/mL).
GMFRs from baseline in:
Toxin A–specific; and
Toxin B–specific neutralizing antibody levels (neutralization units/mL).
Proportions of subjects in each vaccine group with 4-fold, 8-fold, 16-fold, and 
32-fold rises from baseline in:CCI
Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 10
TMF Doc ID: 98.03Toxin A –specific;
Toxin B –specific; and
Both toxin A –and toxin B –specific neutralizing antibody  levels ( neutralization 
units/mL ).
Baseline in the 
above endpoints is the associated last measurement prior to the first 
vaccin ation on Day  1.
For subjects enrolled in the extension stage; at the fourth dose (immediately  before the fourth 
dose), at Day s 8 and 30after the fourth dose, and at Months 6, 12, 18, 24, 30, and 36 after the 
fourth dose :
Proportions of subjects in each vaccine group with
Toxin A –specific neutralizing antibody  level ( neutralization units/mL ) the specified 
threshold for toxin A;
Toxin B –specific neutralizing antibody  level ( neutralization units/mL ) the specified 
threshold for toxin B; and 
Both toxin A –and toxin B –specific neutralizing antibody  levels ( neutralization 
units/mL ) ≥ the specified threshold for toxin A and the specified threshold for 
toxin B, respectively (these parameters will also be assessed at baseline).
Toxin A –
and toxin B–specific neutralizing antibody levels, expressed as GMCs 
(
neutralization units/mL).
GMFRs from baseline in
Toxin A –specific; and
Toxin B –specific neutralizing antibody  levels ( neutralization units/mL ).
Proportions of subjects in each vaccine group with 4-fold, 8-fold, 16-fold, and 
32-fold rise s from baseline in
Toxin A –specific;
Toxin B –specific; and
Both toxin A –and toxin B –specific neutralizing antibody  levels ( neutralization 
units/mL ).

Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 11
TMF Doc ID: [IP_ADDRESS]. Secondary Safety Endpoints
Numbers and proportions of subjects reporting local reactions (pain, erythema, and 
induration) and their severity, as self-reported on e-diaries for to 14 days following the 
fourth vaccination.
Numbers and proportions of subjects reporting systemic events (fever, vomiting, 
diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint 
pain) and their severity, as self-reported on e-diaries for 14 days following the fourth vaccination.
Numbers and proportions of subjects reporting AEs from the time of the fourth
vaccination up to 28 days after the fourth vaccination categorized according to MedDRA. 
Numbers and proportions of subjects reporting SAEs from the time of the fourth
vaccination until 6 months after the fourth dose of vaccine, categorized according to MedDRA.
3.3.
  
3.4.
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 12
TMF Doc ID: 98.03

 
3.5. Safety Endpoints
3.5.1. Adverse Events
A 3-tier approach will be used to summarize AEs. Under this approach, AEs are classified 
into 1 of 3 tiers. Different analyses will be performed for different tiers (see Section 6.5.1 ).
Tier 1 events: These are prespecified events of clinical importance and, if any, will be
maintained in a list in the product’s safety review plan.
Tier 2 events: These are events that are not tier 1 but are “common.” A MedDRA preferred 
term (PT) is defined as a tier [ADDRESS_398966] 5% in any vaccine group.
Tier 3 events: These are events that are neither tier [ADDRESS_398967] vaccination will be excluded from AE analysis, unless the 
severity increases after dosing.  AEs occurring between the informed consent document(ICD) signoff and prior to the first vaccination will be summarized separately.
3.5.2.
  
3.5.3. Reactogenicity Endpoints
Reactogenicity data captured in the e-diary consist of local reactions (erythema/redness, 
induration/swelling, and pain at the injection site), systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain), and use of antipyretics/pain medication to treat symptoms.CCI
CCICCI
Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 13
TMF Doc ID: [IP_ADDRESS].1. Local Reactions
Local reactions reported in the e -diary  are ery thema/redness, induration/swelling, and pain.
Local Reaction s: Presence or Absence
The presence of redness or swelling isto be recorded in the e- diary  as “Yes”or “No”.If 
redness or swelling ispresent, then a second question is to appear requesting the size of the 
affected area; otherwise ,no question 
isto appear. A measuring device with a scale ranging 
from [ADDRESS_398968] whole number. If the area is
larger than the measuring device canmeasure, “21+” isto be selected. Measuring device
units are converted to centimeters according to 1 measuring device unit =0.5 centimeters.
The presence of redness and swelling isdefined according to the following scale:
=., if missing
=
No,if “N o”or minimal redness or swelling ispresent, <2 .5 cm (<5 measuring device
units)
=
Yes, if ≥2.5 cm ( ≥ 5 measuring device units)
These categories (., “No”, “Yes ” ) will be used for derivation of the variables below.
For the data summary  of the presence ( “Y
es” or“No”) of a local reaction, the following 
variables for the 
original lyplanned stage [first 3 vaccinations] and the extension stage [fourth 
vaccination] are required:
Presence ( “Yes ”or “No”) of each local reaction on each day  (Day  [ADDRESS_398969] vaccination on the Day  1, 8, and 30 regim en, and Day 1 to Day 14 after all other 
vaccinations in both regimens) .
Presence ( “Y
es”or “No”) of each local reaction on any  day (Day  [ADDRESS_398970] 
vaccination on the Day  1, 8,and 30 regimen, and Day 1 to Day 14 after all other 
vaccinations in both regimens) .
Presence ( “Y
es”or “No”) of an y local reactions on any day (Day [ADDRESS_398971] 
vaccination on the Day  1, 8 and 30 regimen, and Day 1 to Day 14 after all other 
vaccinations in both regimens) .
Presence ( “Y
es” or“No”) of each local reaction with severe or greater severity  (Grade 3 
or Grade 4, as defined in Table 5) on each day  (Day  [ADDRESS_398972] vaccination 
on the Day  1, 8, and 30 regimen, and Day 1 to Day 14 after all other vaccinations in both 
regimens) . 

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 14
TMF Doc ID: 98.03Table 3 explains the algorithm to derive the presence of a reaction ( “Yes ”or “No”) during a 
given time period.
Table 3. Derived Variables for Each Local Reaction Within a Specified Time Interval
Variabl eaYes (1) No (0) Missing (.)
Any day (Days 1-X) Subject reports the 
reaction as “Yes ”on any 
day from Days 1-XSubject reports the 
reaction as “No”on all X
days or as a combination 
of “No” and m issing on all 
XdaysSubject reports th e 
reaction as missing on all 
Xdays
a.The variable will be derived for each of the 3 local reactions ( pain, erythema/ redness, and 
induration/ swelling), with thetime interval Day 1 toDay X after each vaccination .  X = [ADDRESS_398973] vaccination on the Day 1, 8, and 30 regimen, and X = 14 days after all other vaccinations in both 
regimens. 
For “ any local reaction on any day, ”a similar rule appli es,as specified below in Table 4.
Table 4. Derived Variables for Any Local Reaction Within a Specified Time Interval
VariableaYes (1) No (0) Missing (.)
Any day (Days 1-X) Subject reports any local 
reaction as “Yes ”on any 
dayfrom Days 1-XSubject reports the 
reaction as “No”on all X
days or as a combination 
of “No”and m issing on 
all Xdays on all [ADDRESS_398974] reports all of the local 
reactions as missing on all X
days
a.The variable will be derived for Day 1 toDay Xafter each vaccination .  X = [ADDRESS_398975] 
vaccination on the Day 1, 8 and 30 regimen, and X = 14 after all other vaccinations in both regimens. 
In addition, each local reaction and any local reaction on any day (Days 1- X ) after any
vaccination in the original lyplanned phase will be derived, where X = [ADDRESS_398976] 
vaccination on the Day  1, 8 and 30 regimen, and X = [ADDRESS_398977] 
vaccinations on the Da y 1, 8, and 30 regimen and after each vaccination on the Month 0, 1, 
and 6 regimen.
Maximum Severity for Local Reactions
Erythema/redness and induration/swelling are measured and recorded in measuring device
units (range: 1 - 21+) and then categorized as abs ent, mild, moderate ,or severe based on the 
grading scale in Table 5.  Pain at the injection site will be assessed by  [CONTACT_233031], 
mild, moderate
, or severe according to the grading scale in Table 5.
For each local reaction, the maximum severit y grade of the reaction will be derived for the 
e
-diary  collection period (Day  [ADDRESS_398978] vaccinations on the Day  1, 8, and 30 
regimen, and Day  1 toDay 14 after each vaccination on the Month 0, 1, and 6 regimen) and 

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 15
TMF Doc ID: 98.03after the fourth vaccination of the extension stage in both regimens .  The severity  grading 
scale of the local reaction is presented in Table 5.
The maximum severit y will be derived as follows:
= missing, if all values are missing for all day s (Day  [ADDRESS_398979] vaccination 
on the Day  1, 8, and 30 regimen, and Day 1 to Day 14 after all other vaccinations in both 
regimens )
.
= 0, if the subject reports all reactions as “No”,or a combination of missing and “No”
for all day s (Day  [ADDRESS_398980] vaccination on the Day  1, 8, and 30 regimen,
andDay 1 toDay 14 after all other vaccinations in both re gimens).
= highest grade (maximum severity ) within [ADDRESS_398981] 
vaccination on the Day  1, 8, and 30 regimen, and within 14 day s after all other 
vaccinations in both regimens, if the answer is not “N o”for at least [ADDRESS_398982]’s local reaction 
as Grade 4.  Grade 4 could also be determined if a reaction is reported as an SAE.
Maximum severity  of each local reaction on an y day (Days 1-X) after anyvaccination in the 
originally  planned phase will also be derived, where X = [ADDRESS_398983] vaccination on 
the Day  1, 8 and 30 regimen, and X = [ADDRESS_398984] vaccinations on the Day 1, 8, 
and 30 regimen and after each vaccination on the Month 0, 1 , and 6 regimen.
Table 5. Local Reaction Grading Scale
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Grade 4
Pain Does not interfere 
with activityInterferes with activity Prevents daily 
activity Emergency room 
visit or 
hospi[INVESTIGATOR_323278] a/
Redness2.5 cm to 5.0 cm 
(5 to 10 measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10 cm 
(21 measuring 
device units)Necrosis or 
exfoliative 
dermatitis
Induration/
Swelling2.5cm to 5.0 cm 
(5 to 1 0 measuring 
device units)>5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)>10 cm 
(21 measuring 
device units)Necrosis
Duration of Each Local Reaction
The duration of each local reaction will be calculated as the number of day s from the start of 
the first reported reaction to the resolution of the last reported reaction, inclusive.  Resolution 
is the last day  on which the reaction is recorded in the e -diary  if the reaction lasted [ADDRESS_398985] vaccinations on the Day  1, 8, and 30 regimen, or 14 day s or less for each 

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 16
TMF Doc ID: 98.03vaccination on the Month 0, 1, and [ADDRESS_398986] on the Day  
1, 8, and 30 regimen and for each vaccination on the Month 0, 1, and 6 regimen ,and fourth 
vaccination of the exte nsion stage in both regimens, (the latter will be collected on the case 
report form [ CRF ]).  If there is no known date when the reaction ends, then duration will be 
missing (unknown).  Subjects with no reported reaction have no duration ,because it is not 
applicable. However, the date on which a reaction ended for one vaccination should not be 
after the beginning of the next vaccination. If a reaction or an event is ongoing at the time of 
a subsequent vaccination, the duration will be set to unknown.
Onset of Local Reaction s
The onset day  of each local reaction and an y local reaction since the last vaccination will be 
derived.
For the onset day  of each local reaction, if a subject report sa change in severity  of the local 
reaction, the first day  of reporting that specific local reaction will be used in the calculation.
For the onset day  of an y local reaction, the first day of reporting an y severity  of any  local 
reaction will be used in the calculation.
Maximum Diameter for Erythema/Redness and Induration/Swel ling
The diameter of the affected area for ery thema/redness and induration/swelling within [ADDRESS_398987] vaccinations on the Day  1, 8, and 30 regimen and after each vaccination on the 
Month 0, 1, and 6 regimen, and fourth vaccination in their extension stage of both regimens
will be derived following each vaccination.  The measuring device units are converted to 
centimeters for the anal yses (1 measuring device
unit = 0.5 centimeters).
[IP_ADDRESS]. Systemic Events
The sy stemic events reported in the e -diary  are fever, vomiting, diarrhea, headache, fatigue, 
new or worsening muscle pain, and new or worsening joint pain.  Fever is defined as an oral 
temperature of 38.0C (100.4 F).  The highest temperature for each day will be recorded in 
the e -diary .  Temperature will be collected dail y in the e -diary  from Day  [ADDRESS_398988] vaccina tions on the Day  1, 8, and 30 regimen and after each vaccination on the 
Month 0, 1, and 6 regimen, and fourth vaccination in their extension stage until fever has 
resolved (1 day  of temperature less than 38.0 C [100.4F]). For ongoing fever on Day  [ADDRESS_398989] 
vaccinations on the Day  1, 8, and 30 regimen and after each vaccination on the Month 0, 1, 
and 6 regimen, and fourth vaccination in their extension stage of both regimens , the stop date 
will be recorded in the CRF.  For any  other s ystemic event reported as present, the subjects 
will also note the severity  of the event.

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 17
TMF Doc ID: 98.03Table 6shows the details for the severity  grading scales of each s ystemic eve nt.
Any temperature recorded as <95.0 F (35.0C) and >107.6F (42.0C) will be considered as 
invalid data and will be excluded from the anal ysis.
Table 6. Systemic Event Grading Scale
Mild
(Grade 1)Moderate
(Grade 2)Severe
(Grad e 3)Grade 4
Fever 100.4 -101.1F
(38.0 -38.4C) 101.2 -102.0F
(38.5 -38.9C)102.1 -104.0F
(39.0 -40.0C)>104.0F
(>40.0C)
Vom iting 1-2 times in 
24hours>2 times in 
24hoursRequires IVa
hydrationEmergency room visit or 
hospi[INVESTIGATOR_323279] 2-3 loose stools in 
24 hours4-5 loose stools in 
24 hours6 loose stools in 
24hoursEmergency room visit or 
hospi[INVESTIGATOR_323280]; prevents 
daily activityEmergency room visit or 
hospi[INVESTIGATOR_323281]/ 
TirednessNo interference 
with activitySome interference 
with activitySignificant; prevents 
daily activityEmergency room visit or 
hospi[INVESTIGATOR_323282]; prevents 
daily activityEmergency room visit or 
hospi[INVESTIGATOR_323283]; prevents 
daily activityEmergency room v isit or 
hospi[INVESTIGATOR_059]
a.IV = intravenous.
For the data summary  of the presence ( “Yes ”or “No”) of a s ystemic event, the following 
variables for original lyplanned stage [first 3 vaccinati ons] and extension stage [fourth 
vaccination] are required:
Presence ( “Yes ”or “No”) of each s ystemic event on each day  (Day  1toDay 7after the 
first vaccination on the Day  1, 8, and 30 regimen, Day  1 to Day 14 after all other 
vaccinations in both regime ns
).
Presence ( “Yes ”or “No”) of each s ystemic event on any  day (Day  1toDay 7after the 
first vaccination on the Day  1, 8, and 30 regimen, Day  1 to Day 14 after all other 
vaccinations in both regimens
).
Presence ( “Yes ”or “No”) of an y systemic events on any day (Day  1toDay 7after the 
first vaccination on the Day  1, 8 and 30 regimen, Day  1 to Day 14 after all other 
vaccinations in both regimens
).
Presence ( “Yes ”or “No”) of each systemic event with severe or greater severity (Grade 3 
or Grade 4, as defi ned in Table 6) on each day  (Day  1toDay 7after the first vaccination 

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 18
TMF Doc ID: 98.03on the Day  1, 8 and 30 regimen, and Day  1 to Day 14 after all other vaccinations in both 
regimens )
. 
Maximum severity  of each sy stemic event on any day  (Day  1toDay 7after the first 
vaccination on the Day  1, 8 and 30 regimen, and Day  1 to Day 14 after all other 
vaccinations in both regimens
).
Duration of each s ystemic event .
Onset day  of each s ystemic event since the last vaccination.
The algorithm for derivi ng the presence of a systemic event ( “Y
es”or “No”) during Day  [ADDRESS_398990] vaccination on the Day  1, 8, and 30 regimen or during Day  1 to Day  14 
after all other vaccinations in both regimens is similar to that in Table 3andTable 4forlocal 
reactions.  For the purposes of deriving the variable 
“any systemic event on any  day”(Day  [ADDRESS_398991] vaccination on the Day  1, 8, and 30 regimen or Day  1 toDay 14 after 
all other vacci nations in both regimens), for each day , a sy stemic event including fever, 
vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, or new or worsening 
joint pain will be included as one of the possible sy stemic events. 
In addition, similarly  tolocal reaction s , each s ystemic event, an y systemic event ,and 
maximum severity  of each systemic event on an y dayafter anyvaccination in the original 
planned phase will be derived.
As stated before, onl
y temperature data between 35.0 C and 42.0C will be used for 
derivation of fever ( “Y
es”or “No”) in “any systemic event on any  day.”  The variable of 
“any systemic event on any  day”will be derived similarly  as “any local reaction on any day”
based on the rule stated inTable 3.The d uration of each s ystemic event and the onset day  of 
each s ystemic event since thelast vaccination are derived similarly  as the rules stated above 
for local reactions.  Antipy retics/pain medication used to treat s ymptoms will be handled 
separately  and will not be considered as s ystemic events.
3.5.4. Antipyretics/Pain Medication Use
The following variables will be derived for the use of antipy retics/pain medication to treat 
symptoms:
Medication use to treat fever or pain on each day  (Day  [ADDRESS_398992] 
vaccination on the Day  1, 8, and 30 regimen, Day  1 toDay 14 after all other vaccinations
in both regimens ).
Medication use to treat fever or pain on an y day (Day  [ADDRESS_398993] 
vaccination on the Day  1, 8, and 30 regimen, Day  1 toDay 14 after all other vaccinations
in both regimens )
.
Duration of medication use to treat fever or pain .

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 19
TMF Doc ID: 98.03Onset day  ofmedication use (since the last vaccination) to treat fever or pain .
Duration of medication use to treat fever or pain and onset day  of medicat ion use (since the
last vaccination) to treat fever or pain arederived similarly  as the rules stated above forlocal 
reactions.
3.5.5. Vital Signs and Physical Exam ination
Vital signs will be measured at Visit 1 andinclud eweight, height, sitting blood pressure , 
sitting pulse rate, respi[INVESTIGATOR_2842], and oral temperature.  Body  mass index (BMI ) will be 
calculated based upon weight and height.  Sitting blood pressure, sitting pulse rate, 
respi[INVESTIGATOR_2842], and oral temperature (vaccination visits only ) may  be measu red at each 
subsequent visit (Visit 2 to Visit 
11if clinically  indicated.  A full ph ysical examination will 
be performed at Visit 1 and a targeted ph ysical examination may be performed at each 
postrandomization visit (Visit 2 to Visit 11).  All physical e xamination results will be 
recorded as normal, abnormal, or not done.  Baseline measurements will be the
measurements taken at Visit 1.
3.6.Study Conduct
3.6.1. E-D iary Completion
An e -diary  will be considered transmitted if any  data for the 3 local reactions, the 7 systemic 
events (including fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle 
pain, and new or worsening joint pain), or use of antipy retics/pain medication to treat 
symptoms are present on any  day.  If all data are missing for all items on the e -diary  for all 
days following vaccination (all [ADDRESS_398994] vaccination for both regimens), then the e -diary  will be considered not transmitted.
For transmitted e -
diaries, the following variables will be defined: “ Day 1,” “ Day 2,” “ Day 3, ”
“Day 4,” “ Day 5, ” “ Day 6,” “Day 7,” “ Day 8,” “Day 9,” “ Day 10,” “ Day 11,” “ Day 12,”
“Day 13,” “ Day 14 ” (“ Day 8”to “Day 14” onl y applicable to after Dose 2 , Dose 3 on the 
Day 1, 8, and 30 regimen, and after each dose on the Month 0, 1, and 6 regimen) , and Dose [ADDRESS_398995] agein both regimens, “ Day 1 –Day 7” (for after the first vaccination on 
the Day  1, 8, and 30 regimen), and 
“Day 1 –Day 14”(for after the second and the third 
vaccinations on the Day  1, 8, and 30 regimen, and after each vaccination on the Month 0, 1, 
and 6 regimen ,and fourth vaccination in the extension stage of both regimens).
An e -diary  will be considered completed if all expected data for all day s are available 
(ie,not missing) and data are valid.  Otherwise, the e -diary  will be considered incomplete.  
For any  given day , an e -diary  will be considered complete if all expected data are available.

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 20
TMF Doc ID: 98.03For completed e -diaries, the following variables will be defined for: “Day 1,” “Day 2,” “ Day 
3,” “ Day 4, ” “ Day 5,” “Day 6,” “ Day 7,” “ Day 8, ” “ Day 9,” “ Day 10,” “Day 11,” “Day 12,”
“Day 13,” “ Day 14 ” (“ Day 8”to “Day 14” onl y applicable to after Dose 2 , Dose 3 and Dose 
4intheextension stage of both regimens), “Day 1 –Day 7”(for after the first vaccination on 
the Day  1, 8, and 30 regimen), and 
“Day 1 –Day 14 ”(for after the second andthe third 
vaccinations on the Day  1, 8, and 30 regimen, and after each vaccination on the Month 0, 1, 
and 6 regimen, and fourth vaccination in the extension stage of both regimens).
For e -diaries that are incomplete, an indica tor variable for the percentage of day s without 
data will be derived as follows:
For after the first vaccination on the Day  1, 8, and 30 regimen:
= 1, if data have been transmitted, and are complete for 7 day s (100%)
= 2, if data have been transmitted, and are complete for 6 day s (75% to <100%)
= 3, if data have been transmitted, and are complete for 4 or 5 day s (50% to <75%)
= 4, if data have been transmitted, and are complete for 2 or 3 day s (25% to <50%)
= 5, if data have been transmitted, and are com plete for 0 or 1 day  (<25%)
For after the second and after the third vaccinations on the Day  1, 8, and 30 regimen, and 
after each vaccination on the Month 0, 1, and 6 regimen , and fourth vaccination in the
extension stage in both regimens:
= 1, if data hav e been transmitted, and are complete for 14 day s (100%)
= 2, if data have been transmitted, and are complete for 11, 12 ,or 13 day s 
(75% to <100%)
= 3, if data have been transmitted, and are complete for 7, 8, 9 ,or 10 day s 
(50% to <75%)
= 4, if data h ave been transmitted, and are complete for 4, 5, or 6 day s (25% to <50%)
= 5, if data have been transmitted, and are complete for 0, 1, 2 ,or 3 day s (<25%)
3.6.2. Demographic, Medical History, and Baseline Characteristic Variables
The demographic variables are a ge at randomization/first vaccination visit (in y ears) at Visit 
1, sex , race , ethnicit y, and baseline serostatus of toxin A+/ toxin B+, toxin A–/toxin B+,  
toxin A+/toxin B – , or t oxin A –/toxin B–.  Age will be calculated as (randomization/first 
vaccination date – date of birth + 1)/365.[ADDRESS_398996] lower integer.  
Medical history  will be categorized according to MedDRA.

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 21
TMF Doc ID: [IP_ADDRESS]. Concomitant Treatment
Nonstudy  vaccine received from [ADDRESS_398997] 
vaccinat ion (Visit 6 [Month 2] for subjects on the Day  1, 8, and 30 regimen and Visit 7 
[Month 7] for subjects on the Month 0, 1, 6 regimen), and from 28 day s prior to vaccination 
with the fourth vaccination until Visit 11(Day  30 after the fourth vaccination) for subjects in 
the extension stage of both regimens 
will be recorded on the CRFs.
Concomitant medications taken after signing the ICD until [ADDRESS_398998] 
vaccination (Visit 6 [Month 2] for subjects on the Day  1, 8, and 30 regimen and Visit 7
[Month 7] for subjects on the Month 0, 1, and 6 regimen) andfrom the time of the fourth 
vaccination until Visit 11(Day  30 after the fourth vaccination) for subjects in the extension 
stage of both regimens will be recorded on the CRFs.  Nonstudy  vaccines and conc omitant 
medications will be categorized according to the World Health Organization ( WHO )Drug 
Dictionary (WHODD).
4.ANALYSIS SETS
Data for all subjects will be assessed to determine if subjects meet the criteria for inclusion in 
each anal ysis population prio r to unblinding and releasing the database , and classifications 
will be documented per standard operating procedures (SOPs) .
4.1.Evaluable Analysis Set
For each vaccination regimen, the evaluable immunogenicity  population will be defined for 
each stage (origin al planned stage [first 3 vaccinations] and extension stage [fourth 
vaccination] separatel y.
For the 
Day 1, 8, and 30 , regimen, the evaluable immunogenicity  population in the original 
planned stage will include all subjects who:
1.Are eligible for the study at randomization.
2.Have received all 3study vaccinations for the vaccine formulations to which they  are 
randomized.
3.Have blood drawn for assay  testing on Day  37 (Visit 5) within 7 to 14 day s after the 
vaccination on Day  30 (Vaccination 3 at Visit 4) and the sample from this blood draw 
provides at least 1valid and determinate assay  result .
4.Have no major protocol violations as determined by  [CONTACT_309365].
The evaluable immunogenicity  population in the extension stage will include all subjects 
who:
1.Are eligible for the study extension stage atre-randomization .

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 22
TMF Doc ID: 98.032.Have received the fourth study  vaccination with the vaccine formulations to which they  
are randomized.
3.Have blood drawn for assay  testing on Day  8 after vaccination 4 (Visit 10) within 7 to 14 
days after 
vaccination 4 (Visit 9 )and the sample from this blood draw provides at least [ADDRESS_398999] no major protocol violations as determined by  [CONTACT_309365].
For the Month 0, 1, and 6 regimen, the evaluable immunogenic ity population in the 
original lyplanned stage will include all subjects who:
1.
Are eligible for the study at randomization.
2.Have received all 3study vaccinations for the vaccine formulations to which they  are 
randomized.
3.Have blood drawn for assay  testing at Month 7 (Visit 7) within 20 to45days after the 
vaccination at Month 6 (Vaccination 3 at Visit 5) and the sample from this blood draw 
provides at least 1valid and determinate assay  result .
4.Have no major protocol violations as determined by  [CONTACT_309365].
The evaluable immunogenicity  population in extension stage will include all subjects who:
1.Are eligible for the study extension stage atre-randomization .
2.Have receiv ed fourth study  vaccinations with the vaccine formulations to which they  are 
randomized.
3.Have blood d
rawn for assay  testing on Day  8 after vaccination 4 (Visit 10) within 7 to 14 
days after 
vaccination 4 (Visit 9 )and the sample from this blood draw provides at least [ADDRESS_399000] no major protocol violations as determined by  [CONTACT_309365].
The evaluable immunogenicity  population will be the primary  analy sis population for all 
immunogenicity  endpoints. The immunogenicity  results will be summarized according to the 
vaccine group as randomly  assigned.
Subjects vaccinated but not randomized and subjects randomized but who receive the wrong
vaccine will be excl uded from the evaluable immunogenicity  population.
4.2.Modified Intent -to-Treat Analysis 
Set
For each vaccination regimen, the modified intent- to-treat ( mITT) population will be defined 
for each stage separatel y.  The mITT population for each regimen at each stage (original 

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 23
TMF Doc ID: 98.03planned stage or extension stage) will include all subjects randomized in that stage who have 
at least 1valid and determinate assay  result for the proposed anal ysis.  This analysis set is for 
the purpose of immunogenicity  anal ysis, for which it will be the secondary anal ysis 
population.  I n the immunogenicity  data analy sis based on 
the mI TT population, results will 
be summarized according to the vaccine group as randomly  assigned.
Subjects randomized but not vaccinated will be included in the mITT population for 
immunogeni city anal ysis if any  valid and determina te assay  results are available.
Subjects vaccinated but not randomized will b e excluded from the mI TT pop ulation.
4.3.Safety Analysis Set
The safet y population will include all subjects who receive at least 1dose of the 
investigational product. Separate safet y populations will be defined for each regimen at each
stage (original planne d stage orextension stage) . In the safet y anal ysis based on the 
safet y 
population, subjects will be grouped according to the vaccine actually  received.  Subjects 
who lack an y safety data for a parti cular vaccination will be excluded from anal ysis.
Subject s vaccinated but not randomized will be included in the safet y population for safety 
analysis, and results from these subjects will be reported under the group corresponding to 
the vaccine they  actually  received .
Subjects who were randomized but received the wrong vaccine will be included in the safet y 
population for safet y analy sis, and results from these subjects will be reported under the 
group corresponding to the vaccine they  actually  received.
4.4. Other Analysis Sets
No other anal ysis sets wil lbe defined.
5.GENERAL METHODOLOGY AND CONVENTIONS
The analysis for first clinical study  report (CSR) will be performed when all subjects have 
completed Visit [ADDRESS_399001] the safet y of subjects and to support internal program- level 
decision making .No multiplicity  adjustments will be made on the descriptive anal yses.All 
CIs will be created at nominal level in th isanaly sis.  For the origina l ly planned stage, data 
will be anal yzed separately  for each 3- dose regimen: Day s 1, 8, and 30 and Months 0, 1, and 
6.For 
the extension stage, data will also be anal yzed separatel y for original lyassigned 
3-dose regimen (Day s 1, 8, and 30, Months 0, 1, and 6).

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 24
TMF Doc ID: 98.035.1. Hypotheses and Decision Rules
This is a Phase 2 study  to assess the safety , tolerability , and immunogenicity  of 2 antigen 
dose levels (100 µg and 200 µg total toxoid) of aluminum hy droxide –containing C difficile
vaccine when administered as a 3 -dose regimen: either at Day s 1, 8, and [ADDRESS_399002] 3 doses of C difficile vaccine 
(100 µg or 200 µg) will be enrolled into an extension stage. These subjects will receive a 
fourth dose of either C difficile vaccine at the same antigen dose level (100 µg or 200 µg) as 
they received previously  orplacebo, approximately  [ADDRESS_399003] dose. These 
subjects will be followed for a further 3 years (visits approximately  every  6 months) to assess 
antibody  persistence. Subjects originally  randomized to placebo in either dosing regimen
will not continue into the extension stage.
No formal statistical h ypothesis test will be performed. A descriptive estimation approach 
will be used to assess all study  objectives regarding safet y and immunogenicity  (PI, PS, SI , 
SS
,and E) in the study .
Point estim ates and nominal 95% CI s will be provided for all safety and immunogenicity 
endpo ints at each planned anal ysis.
No formal multiplicity  adjustments will be applied due to multiple endpoints or multiple 
analysesof the same endpoint.
5.2.General Methods
Unless otherwise explicitly  stated, descriptive statistics for continuous variables are n, mean, 
median, standard deviation, minimum, and maximum.  Descriptive statistics for categorical 
variables are the percentage (%) and the numerator (n) and the denominator (N ) used in the 
percentage calculation.
5.2.1. Analyses for Binary Data
For immunogenicity  results, the exact 2- sided 95% CIs (Clopper -Pearson CI s) will be 
provided for each vaccine group and sampling time point for the proportions of subjects, as 
defined in Section 3.2 with toxin A – and toxin B– specific neutralizing antibody  levels greater 
than or equal to the specified thresholds, and with specified fold rise changes from baseline 
in toxin A –and toxi n B– specific neutralizing antibody  levels.
For each proportion of the immunogenicity  results, aline plot of the proportions and the 
associated 95% CIs over the sampling time points will be provided by  [CONTACT_29299] 
(including placebo).
Similarly ,for the safet y results including rese arch-related injury  during the extension stage , 
the exact 2- sided 95% CIs will be provided by  [CONTACT_323289] y 
endpoints, proportions of subjects reporting local reaction s,systemic event s, and AE s 
(includin g AEs occurring within the first 30 minutes after each vaccination and for the fourth 
dose in the extension stage ).

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 25
TMF Doc ID: 98.03For tier [ADDRESS_399004] method for deriving the 95% CI for the risk difference 
and p -value proposed b y Chan and Zhang (19 99)will be used to compare vaccine with 
placebo.
For tier 2AEs, theMiettinen and Nurminen method will be used to derive the 95% CI for the 
risk difference between vaccine and placebo.
The exact CIs for the various proportions of individual groups will be computed using the 
Fdistribution.  I f r is the number of responses and n is the number of subjects, then it follows 
that p=r/n is the estimate of the proportion of response s.  An exact 95% CIcan be comput ed 
by [CONTACT_323290] [ADDRESS_399005],
))1 ( (  r n rFrFp
LL
L
and for the upper limit PU,
UU
UF r r nF rp) 1 ( ) () 1 (
  
where FLis the quantile from the F distribution for α=0.025, with numerator degrees of 
freedom equal to 2r and denominator degrees of freedom equal to 2(n –r+1).  F Uis the 
quantile from the F distribution for α=0.975, with numerator degrees of freedom equal to 
2(r+1) and denominator degrees of freedom equal to 2(n
–r).  When r equals 0, FLshould be 
set equal to 1.0 so PLequals 0.  When r equals n, FUshould be set equal to 1.0 so 
PUequals 
1.0. 
The CIusing the F distribution is described in Collett (1991) and implemented in SAS PROC 
FREQ.
5.2.2. Analyses for Continuous Data
The C difficile toxin A – and toxin B–specific neutralizing antibody  levels at each blood 
sampling time point will be summarized by  [CONTACT_323291] 95% CI s for each 
vacci ne group.  The GMC will be calculated as the mean of the assay  results after making the 
logarithm transformation and then back transformation to its original scale.  Two-sided 95% 
CIswill be constructed by  [CONTACT_323292] t distribution.
For each C difficile toxin A– and toxin B–specific neutralizing antibody  levels, a line plot of 
the GMC and the associated 95% CI over the sampling time points will be provided b y 
vaccine group, separatel y for each assigned 3 -
dose regimen in the original planned stage and 
for the fourth dose in the extension stage .

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 26
TMF Doc ID: 98.03The GMFRs in toxin A– and toxin B–specific neutralizing antibody  levels from before 
vaccination to after v accination will be summarized for each vaccine group by  [CONTACT_323293]. These CIs are also 
computed by  [CONTACT_323294] s using the Student t distribution for the mean 
differenc e of measures on the logarithmically  transformed assay  results.
Fortheoriginal lyplanned stage, e mpi[INVESTIGATOR_323284] (RCDCs) 
will be presented graphically  for each C difficile toxin A –
and toxin B–specific neutralizing 
antibod
y levels for each vaccine group (including placebo) at Day  37 (Visit 5) and all blood 
sampling time points after Day  37 for the Day  1, 8, and 30 regimen, and at Month 7 (Visit 7) 
and all blood sampling time points after Month 7 for the Month 0, 1, and 6 re gimen.
Fortheextension stage, RCDCs will also be presented graphically  for each Cdifficile toxin 
A– and toxin B–specific neutralizing antibody  level for each vaccine group at Day 8 after 
V
accination 4 (Visit 10) and all blood sampling time points a fter Visit 10.
5.3. Methods to Manage Missing Data
5.3.1. Immunogenicity Data
For any  C difficile toxin A –or toxin B –specific neutralizing antibody  level that is below t he 
LLOQ , the l ower l imit of detection (LOD) ,defined as 0.5 × LLOQ ,will be assigned.  No 
other missing assay  data will be imputed in the analy ses.  All immunogenicity  anal yses will 
be performed after the imputation of the antibody
 levels that are below the LLOQ.
For each C difficile toxin A –or toxin B –specific neutralizing antibody  result, the number of 
s
ubjects with missing values at each blood sampling point will be provided.
5.3.2. Safety Data
Handling of missing information related to safet y data, such as missing or partially  missing 
date, will be in accordance with [COMPANY_007] reporting standards.
For derived var iables in reactogenicity  data, if any day  of the 7- day e-diary  is available, the 
“Day 1 –Day 7”data will be considered as nonmissing for anal yses after Vaccination 1 on 
the Day  1, 8, and 30 regimen and if any  of the 14 -day e-diary  is available, the “Day 1 –
Day 14”data will be considered as nonmissing for anal yses after Vaccination s2 and 3 on the 
Day 1, 8, and 30 regimen, and after each vaccination on the Month 0, 1, and 6 regimen , and 
Vaccination 4 in the extension stage.
  The proportion of subjects with missing reactogenicity  
data will also be summarized by  [CONTACT_323295]. The denominator 
will be the number of subjects who receive the scheduled vaccination.

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 27
TMF Doc ID: 98.036.ANALYSES AND SUMMARIES
6.1.Primary Endpoint (s)
6.1.1. Primary Immunogenicity Endpo ints
[IP_ADDRESS]. Primary Analysis
Endpoints: Primary  immunogenicity endpoints in Section 3.1.1
oAnaly sis time points: 
For the D ay 1, 8, and 30 regimen : Day  37
For the Month 0, 1, and 6 regimen: Month 7 
oAnalysis populations :  Evaluable immunogenicity and mITTpopulations
oAnaly sis methodology :  See Section 5.2.1
oSupporting objective: Primary i
mmunogenicit y objective s
Reporting 
Results :
The nume rator and denominator used for the proportion and associated 95% CI at Day  37 
or Month 7 will be presented for each vaccine group in each regimen (Days 1, 8, and 30 
or Months 0, 1, and 6).
Figures :
The a ntibody  r esponse line plot of proportions and t he ass ociated 95% CI at Day  37 or 
Month 7 will be provided by  [CONTACT_29299], separately  for each regimen.
6.1.2. Primary Safety E ndpoints
Endpoints: 
Primary  safety  endpoints in Section 3.1.2
oAnaly sis time points
:
Local reactions and systemic events: Up to 14 days following each vaccination
AEs: F romthefirst vaccination up to [ADDRESS_399006] vaccination
SAEs: From the first vaccination until [ADDRESS_399007] vaccination
oAnaly sis population:  Safety population
oAnaly sis methodology :  Descriptive ; see Section 5.2.1
oSupporting objective: Primary safety objective

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 28
TMF Doc ID: 98.03Reporting R esults:
The n umber, pr oportion , and associated 95% CI willbe presented for each vaccine group
in each regimen (Day s 1, 8, and 30 or Months 0, 1, and 6).
6.2.Secondary Endpoints
6.2.1.
Secondary Immunogenicity Endpoint s
Endpoints: Secondary immunogenicity endpoints described in Section 3.2
Endpoints: GMC s for toxin A –and toxin B
–specific neutralizing antibody  levels
oAnaly sis time points
:
Original planned stage:
For the D ay 1, 8, and 30 regimen : Day s 1, 8, 15, 30, and 37 and Months 2, 4, 
7,and13
For 
the Month 0, 1, and 6 regimen: Days 1, 30,and 37, Months 2 and6, Day  187, and 
Months 7, 12, and 18
Extension stage:
at the fourth dose (immediately  before the fourth dose ), at Day s 8and30after the 
fourth dose, and at Month
s 6, 12, 18, 24, 30, and 36 after the fourth dose :
oAnaly sis populations :  mITT and evaluable immunogenicity population s
oAnaly sis methodology :  See Section 5.2.2
oSupporting objective: Secondary  immunogenicity objective
Reporting R
esults :
The n umber,GMC , and associated 95% CI at the above analy sis time points will be 
presented for each vaccine group in each regimen (Day s 1, 8, and 30 or Months 0, 1, 
and6)separatel y for the original lyplanned stage and the extension stage
Figures :
The a ntibody - r esponse line plot of GMCs and the associated 95% CI for each toxin A –
and toxin B–specific neutralizing antibody  level at the above analy sis time points will be 
presented b y vaccine group, separately for each regimen in the original lyplanne d stage 
and the extension stage .
Endpoints : GMFRs from baseline in toxin A –and toxin B–specific neutralizing antibody  
levels

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 29
TMF Doc ID: 98.03oAnaly sis time points:
Original planned stage:
For the D ay 1, 8, and 30 regimen : Day s  8, 15, 30, and 37, and Months 2, 4, 7 and13
For 
the Month 0, 1, and 6 regimen: Days 30 and37, Months 2 and6, Day  187, and 
Months 7, 12, and 18
Extension stage:
at the fourth dose (immediately  before the fourth dose ), at Day s 8 and 30after the 
fourth dose, and at Month
s 6, 12, 18, 24, 30, and 36after the fourth dose
oAnaly sis populations :  mITTandevaluable immunogenicity  population s
oAnaly sis methodology :  See Section 5.2.2
oSupporting objective: Secondary  immunogenicity objective
Reporting 
Results:
The sample size, GMFR , and associated 95% CI at the above analy sis time points will be 
presented for each vaccine group in each 3- dose regimen (Day s 1, 8, and 30 or Months 0, 
1, and 6) separatel y for the original lyplanned stage and theextension stage.
Endpoints: Proportions with 4-fold, 8-fold, 16-fold, and 32fold rise sfrom baseline in 
toxin A –specific , t oxin B –specific ,and both toxin A – and toxin B– specific neutralizing 
antibody  levels
oAnaly sis time points:
Original planned stage:
For the D ay 1, 8, and 30 regimen : Day s 8, 15, 30, and 37 and Months 2, 4, 7, and13
For 
the Month 0, 1, and 6 regimen : Day s 30and 37, Months 2 and6, Day  187, and 
Months 7, 12, and 18
Extension stage:
at the fourth dose (immediately  before the fourth dose ), at Day s 8 and 30after the 
fourth dose, and at Month
s 6, 12, 18, 24, 30, and 36 after the fourth dose
oAnaly sis populations :  mITT and evaluable immunogenicity  population s
oAnaly sis methodology :  See Section 5.2.1
oSupporting objective: Secondary  immunogenicity objective

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 30
TMF Doc ID: 98.03Reporting R esults:
The numerator and denominator used for proportion, propo rtion,and associated 95% CI
at 
the above anal ysis time points will be presented for each vaccine group in each
regimen (Day s 1, 8, and 30 or Months 0, 1, and 6) separately  for the original lyplanned 
stage and the extension stage .
Endpoints: Proportions with toxin A –specific neutralizing antibody  levels the specified 
threshold for toxin A; proportio ns with toxin B –specific neutralizing antibody  levels the
specified threshold for toxin B ; proportions with b oth toxin A – and toxin B–specific 
neutralizing 
antibody  levels the specified threshold for toxin A and the specified threshold 
for toxin B, respectivel y.
oAnaly sis time points:
Original planned stage:
For the D ay 1, 8, and 30 regimen : Day s 1, 8, 15, and 30 and Months 2, 4, 7, and13
For 
the Month 0, 1, and 6 regimen: Days 1, 30,and 37, Months 2 and6, Day  187, and 
Months 12 and 18
Extension stage:
at the fourth (immediately  before the fourth dose ), at Day s 8 and 30after the fourth 
dose, and at Months 6, 12 , 18, 24, 30, and 36 after the fourth d ose
oAnaly sis populations :  mITT and evaluable immunogenicity  populations
oAnaly sis methodology :  See Section 5.2.1
oSupporting objective: Secondary  immunogenicity objective
Reporting R esults:
The numerator and denominator used for proportion, the propo rtion, and associated 95% 
CI at the above anal ysis time points will be presented for each vaccine group ineach
regimen (Day s 1, 8, and 30 or Months 0, 1, and 6) separately  for the original lyplanned 
stage and the extension stage.
Figures :
The a ntibody - r esponse line plot of proportions and the associa ted 95% CI at the above 
analysis time points will be presented by  [CONTACT_29299], separatel y for each regimen in 
the original lyplanned stage and theextension stage.
6.2.2. Secondary Safety Endpoints
Endpoints: Secondary  safet y endpoints in Section 3.2.2

Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 31
TMF Doc ID: 98.03oAnalysis time points :
Local reactions and systemic events: Up to 14 days following fourth vaccinationAEs: From the time of the fourth vaccination up to 28 days after the fourthvaccinationSAEs: From the time of the fourth vaccination up to 28 days after the fourth vaccination 
oAnalysis population :  Safety population
oAnalysis methodology :  Descriptive; see Section 5.2.1
oSupporting objective: Secondary safety objective
Reporting Results:
The number, proportion, and associated 95% CI will be presented for each vaccine group 
in each originally assigned regimen (Days 1, 8, and 30 or Months 0, 1, and 6).
6.3.
 
 
Table 7.  CCI
CCI
CCI
CCI
Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 32
TMF Doc ID: 98.03Table 7.  
Subgroup analyses of primary and selected secondary immunogenicity endpoints
(proportions equal to or above the prespecified threshold, proportions achieving >= 4 fold from baseline and GMCs) will be conducted by [CONTACT_323296] (65 to 69 years, 70 to 74 years,75 to 79 years, and 80 to 85 years), separately for each regimen, to explore the impact of age on the immunogenicity results. Similar subgroup analyses (proportions equal to or above the prespecified threshold, proportions achieving >= 4 fold from baseline and GMCs) will be conducted by [CONTACT_323297].  All subgroup analyses will 
be performed based on the evaluable immunogenicity population.
For the statistical analysis related to endpoints of proportions of subjects achieving 1) toxin 
A–specific, 2) toxin B–specific, and 3) toxin A– and toxin B–specific neutralizing antibody 
levels the specified thresholds defined in Section 3.1.1 , alternative levels/thresholds may be 
considered.
6.4. Baseline and Other Summaries and Analyses
6.4.1. Baseline Summaries
The number and percentage of subjects with baseline serostatus of toxin A+/toxin B+,
toxin A–/toxin B–, toxin A+/toxin B–, and t oxin A–/toxin B+ will be provided and included 
in a subject demographic summary table.CCI
CCI
Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 33
TMF Doc ID: [IP_ADDRESS]. Study Conduct
[IP_ADDRESS]. Subject Disposition ,Vaccination Administration, Blood Samples, and Screen 
Failures
The number and percentage of subjects who are randomized will be included in the subject 
disposition summary fortheoriginal lyplanned stage : subjects who withdraw during the 
vaccination phase (Visit 1 to Visit 4 on the Day  1, 8 and 30 regimen; Visit 1 to Visit 5 on the 
Month 0, 1, and 6 regimen), complet
e the vaccination phase, , and withdraw after the 
vaccination phase will be summarized. The number and percentage of subjects who are re
randomized will be included in the subject disposition summary for the extension stage : the 
number and percentage of su bjects who complete the study  and withdraw after fourth 
vaccination will be summarized .The reasons for withdrawal will also be tabulated.  The 
reasons for withdrawal will be those specified in the database; no rewording/recoding will be 
done.
Subjects exc luded from the evaluable immunogenicity  population will also be summarized 
with reasons for exclusion.
The number and percentage of subjects randomized, vaccinated, and providing blood 
samples within the protocol -specified time frame, as well as before and after the specified 
time frame, will be tabulated for the original lyplanned stage . In addition, t he number and 
percentage of subjects rerandomized, vaccinated, and providing blood samples within the 
protocol -specified time frame, as well as before and af ter the specified time frame, will be 
tabulated fortheextension stage.
A listing of noncompliant vaccine administration will be provided.  The protocol deviations 
will also be listed.  Subjects who do not receive the vaccine as randomized will be listed as 
well.  A listing of subjects who withdrew because of AEs will be provided.
All randomized subjects will be used to generate these tables.  All of the summary  tables will 
be presented for each vaccine group and for the total, separatel y for each assigned 3-dose 
regimen in the 
original lyplanned stage and the extension stage .
Subjects who sign the I CD but are screen failures will be also summarized separately  for 
each assigned 3 -dose regimen in the original lyplanned stage .
[IP_ADDRESS]. Demographic, Medical History, an d Baseline Characteristics
Descriptive summary  reports for demographic characteristics will be provided for each 
vaccine group, separatel y for each regimen 
in the original lyplanned stage for the evaluable 
immunogenicity  and mITT anal ysis populations.
Desc riptive summary  reports for medical history  will be provided for each vaccine group, 
separately  for each regimen for the safet y population only intheoriginal lyplanned stage .

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 34
TMF Doc ID: [IP_ADDRESS].3. E-D iary Completion
Variables defined in Section 3.6.[ADDRESS_399008] s.  All safet y summaries will be provided by [CONTACT_323298] 3- dose regimen (Day s 1, 8, and 30 and Months 0, 1, and 6)
in the origina llyplanned st age and for each original assigned regimen in the extension stage .
6.5.1. Adverse Events
It should be recogni zed that most studies are not designed to reliabl y demonstrate a causal 
relationship between the use of a pharmaceutical product and an AEor a group of 
AEs. 
Except for select events in unique situations, studies do not employ  formal adjudication 
procedure s for the purpose of event classification. As such, safet y analysis is generall y 
considered as an exploratory  anal ysis and its purpose is to generate h ypotheses for further 
investigation. The 3- tier approach facilitates this exploratory  anal ysis.There wil l be no 
adjustment for multipl e comparisons in the anal yses.
For tier 1 and tier 2 events, the proportion of AEs observed in each vaccine group will be 
presented along with the point estimates and associated 95% CIs of the risk difference 
(thedifference o f incidence rates) between each vaccine and placebo.
For tier 1 events, 95% CI s will be calculated using the exact methods proposed by  [CONTACT_323299] 5.2.1.
For tier 2 eve nts, 95% CI s will be calculated using the Miettinen and Nurminen method
described in Section 5.2.1 .
For tier 1 events ,
p-values from Chan and Zhang’s method will be calculated and included in 
the presentations. AEs will be arranged in the output sorted in descending order of 
point 
estimate sof the risk difference (the difference of incidence rates) within system organ class.

Protocol B5091009 (PF-06425090) Statistical Analysis Plan Amendment 2.0
DMB02-GSOP-RF02 3.0 STATISTICAL ANALYSIS PLAN TEMPLATE 30-Jun-2015
Page 35
TMF Doc ID: [IP_ADDRESS]. Reactogenicity Data
The derived endpoints ( Section 3.5.3 ) for each local reaction, systemic event, and use of 
antipyretics/pain medication to treat symptoms will be summarized.
The presence and maximum severity of the local reaction and systemic event at “any day
(Day 1 – Day 7)” following the first vaccination on the Day 1, 8, and 30 regimen “any day (Day 1 – Day 14)” following the second and third vaccinations on the Day 1, 8, and 30 regimen, and “any day (Day 1 – Day 14)” following each vaccination on the Month 0, 1 and 6 regimen in originally planned stage and fourth vaccination in the extension stage for both regimens will be summarized with 95% Clopper-Pearson CIs.
The presence of each local reaction and systemic event on any day (Day 1- X), any local 
reaction on any day (1-X), maximum severity of each local reaction and systemic event onany day (Day 1-X) following anyvaccination on the Day 1, 8, and 30 regimen and the 
Month 0, 1, and 6 regimen in the originally planned stage will also be summarized with Clopper-Pearson CIs,  where X = [ADDRESS_399009] vaccination on the Day 1, 8 and 30 regimen, and X = 14 after all other vaccinations in both regimens. For local reactions, systemic events, and use of antipyretic/pain medication to treat symptoms, descriptive summary statistics of the maximum duration of the event will be provided.
For the onset of local reactions, systemic events, and use of antipyretic/pain medication to 
treat symptoms, descriptive summary statistics of the onset day will be provided.
[IP_ADDRESS]. Unscheduled Visits (Unplanned Visits) for Severe Reactions
A listing will be generated for all of the subjects with unscheduled/unplanned visits because 
of severe (Grade 3) and Grade [ADDRESS_399010] 30-minute observation period will be summarized by [CONTACT_323300] 3-dose regimen in the originally planned stage and also summarized by [CONTACT_323301] 3-dose regimen in the extension stage . Also, Clopper-Pearson 95% CIs will be included with the percentages.
 
6.5.5. Physical Examinations, Including Vital Signs
Descriptive summary tables will be provided in accordance with [COMPANY_007] reporting standards.
CCI
Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 36
TMF Doc ID: [IP_ADDRESS]. Nonstudy Vaccination and Nonstudy Medication
Nonstudy  vaccination and nonstudy  medication summaries will be provided with descriptive 
summaries.
7. INTERIM ANALYSES
7.1. Introduction
This is a Phase 2, placebo- controlled, rando mized, observer -blinded study .
In ad dition to the planned anal yses described in Section 7, unblinded safety data from the 
study  will be reviewed by  [CONTACT_4617] (DMC) approximately  
twice a year as part of program -level safet y review activities, governed b y a program -level 
DMC charter. 
Foreach anal ysis described in this SAP, the a nalysis data sets used to create the tables, 
listing s,and figures will be provided to the appropriate sponsor personnel to support the 
planned data review and decision making.
7.2.Interim Analyses and Summaries
Four interim analy ses are planned for the study  and described as below. An internal r eview 
committee (I RC) will be established to review the interim analy ses results and make 
recommendations. The IRC may  request and review additional anal ysis as needed. An IRC 
charter will be finalized prior to the first interim analy sis with details of the interim analy ses 
objectives, decision guidance, and method of maintaining the study  blinded following 
appropriate [COMPANY_007]’s SOPs.
A list of protocol dev iations will be compi[INVESTIGATOR_323285], and 
will be updated prior to each follow -up interim analy sisand the final analysis.  Subjects who 
do not meet the eligibility criteria and subjects who have major protocol violations wi ll be 
excluded from the evaluable immunogenicity population.  A major protocol violation is a 
protocol violation that, in the opi[INVESTIGATOR_323286], would materiall y affect assessment of 
immunogenicity , eg, subject receipt of a prohibited vaccine or medication that might affect 
immune response or a medication error with suspected decrease in potency of the vaccine.  
Clinicians will identify  those subjects with protocol violations before each of the interim 
analyses and thefinal analy sis of immunogenici ty results.
7.2.1. First Interim Analysis
The first anal ysis is planned for the study  when Month [ADDRESS_399011] anal ysis is to determine the suitability  of the Day  1, 8 and 30 
regimen for further stud y.

Protocol B5091009 (PF-06425090 ) Statistical Analysis Plan Amendment 2.0
DMB02- GSOP -RF02 3.0STATI STICAL ANALYSI S PLAN TEMPLATE 30 -Jun-2015
Page 37
TMF Doc ID: [IP_ADDRESS]. Second Interim Analysis
The second interim anal ysis is planned for the study when Month [ADDRESS_399012] –Dose 3 data are available 
from all continuing subjects (Month 7 for subjects receiving the Day  1, 8 and 30 regimen and 
Month 12 for subjects receiving the Month 0, 1 and 6 regimen). All available 
immunogenicity  and safety  data will be include in the primary  analy sis.
The objective of the fourth analysis is to support regulatory  interactions.
8.REFERENCES
1.Collett D.   Modelling binar y data.  London: Chapman & Hall; 1991.
2.Chan I SF, Zhang Z. Test -based exact confidence intervals for the difference of two 
binomial p roportions. Biometrics 1999;55:1201 -9.
3.Miettinen O, Nurminen M. Comparative anal ysis of two rates. Stat Med 1985;4:213 -
26.
